A prospective study on different methods for the treatment of choroidal neovascularization. the efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration

Medical Science Monitor

Volumn 18, Issue 6, 2012, Pages

  Nowak, Michał S ^a   Jurowski, Piotr ^a   Grzybowski, Andrzej ^b   Goś, Roman ^a   Pastuszka, Mirosław ^a   Kapica, Andrzej ^a   Śmigielski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b City Hospital   (Poland)

Author keywords

Age related macular degeneration; Intravitreal bevacizumab; Transpupillary thermotherapy; Verteporfin photodynamic therapy

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RANK SUM TEST; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TRANSPUPILLARY THERMOTHERAPY; VISUAL ACUITY;

EID: 84863548218     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882907     Document Type: Article

References (32)

1. Nowak M, Gnitecki W, Jurowski P: The role of retinal oxygen metabolism in the origin of age-related macular degeneration (AMD). Klin Oczna, 2005; 107: 715-18
2. Cheng CL, Saw SM, Pang CE, Chee C: Age-related macular degeneration in Singapore. Sigapore Med J, 2009; 50: 126-31
3. Yip PP, Woo CF, Tang HH, Ho CK: Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol, 2009; 93: 754-58
4. Odergren A, Algvere PV, Seregard S et al: Vision-related function after low-dose transpupilary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Acta Ophthalmol, 2010; 88: 426-30
5. Augustin AJ, Scholl S, Kirchhof J: Treatment of neovascular age-related macular degeneration: Current therapies. Clinical Ophthalmology, 2009; 3: 175-82
6. Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol, 2001; 119: 198-207
7. Okada K, Kubota-Taniai M, Kitahashi M et al: Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration. Clinical Ophthalmology, 2009; 3: 483-88
8. Chan WM, Lai TY, Wong AL et al: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study. Br J Ophthalmol, 2006; 90: 337-41
9. Rosenfeld PJ, Brown DM, Heier JS: Ranibizumab for neovascular age-related macular degeneration. N Eng J Med, 2006; 355: 1419-31
10. Brown DM, Kaiser PK, Michels M: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med, 2006; 355: 1432-44
11. Conrad PW, Zacks DN, Johnson MW: Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clinical Ophthalmology, 2008; 2: 727-33
12. Melamud A, Stinnett S, Fekrat S: Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol, 2008; 146: 91-95
13. Bashshur ZF, Haddad ZA, Schakal AR et al: Intravitreal bevacizumab for treatment of neovascular age-relatedmacular degeneration: the second year of prospective study. Am J Ophthalmol, 2009; 148: 59-65
14. Arevalo JF, Sanchez JG, Wu L et al: Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology, 2010; 117: 1974-81
15. Schouten JS, La Heij EC, Webers CA et al: A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthaalmol, 2009; 247: 1-11
16. Reichel E, Berrocal AM, Ip M et al: Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology, 1999; 106: 1908-14
17. Newsome RS, McAlister JC, Saeed M, McHugh JD: Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularization. Br J Ophthalmol, 2001; 85: 173-78
18. Odergren A, Algvere PV, Seregard S, Kvanta A: A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Br J Ophthalmol, 2008; 92: 757-61
19. Barbazetto I, Burdan A, Bressler NM et al: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Verteporfin in Photodynamic Therapy Study Group. Arch Ophthalmol, 2003; 121: 1253-68
20. Subramanian ML, Abedi G, Ness S et al: Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomized clinical trial. Eye, 2010; 24: 1708-15
21. Ferraz D, Bressanim G, Takahashi B et al: Three-monthly intravitreal injections for neovascular age-related macular degeneration: short-term visual acuity results. Eur J Ophthalmol, 2010; 20: 740-44
22. Fong DS, Custis P, Howes J, Hsu JW: Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology, 2010; 117: 292-302
23. Stepien KE, Rosenfeld PJ, Puliafito CA et al: Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina, 2009; 29: 1067-73
24. Landa G, Amde W, Doshi V et al: Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica, 2009; 223: 370-75
25. Arias L, Caminal JM, Casas L et al: A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol, 2008; 92: 1636-41
26. Wan MJ, Hooper PL, Sheidow TG: Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab. Can J Ophthalmol, 2010; 45: 375-80.
27. Smith BT, Dhalla MS, Shah GK et al: Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina, 2008; 45: 375-80
28. Das RA, Romano A, Chiosi F et al: Combined treatment modalities for age related macular degeneration. Curr Drug Targets, 2011; 12: 182-89
29. Christoforidis JA, Tecce N, Dell'omo R et al: Age related macular degeneration and visual disability. Curr Drug Targets, 2011; 12: 221-33
30. Caputo M, Zirpoli H, Di Benedetto R et al: Perspectives of choroidal neovascularization therapy. Curr Drug Targets, 2011; 12: 234-42
31. Kowalski M, Bielecka-Kowalska A, Oszajca K et al: Manganese superoxide dismutase (MnSOD) gene (Ala-9Val, Ile58Thr) polymorphism in patients with age-related macular degeneration (AMD). Med Sci Monit, 2010; 16(4): CR190-96
32. Wysokinski D, Synowiec E, Chmielewska M et al: Lack of association between the c.544G>A polymorphism of the heme oxygenase-2 gene and age-related macular degeneration. Med Sci Monit, 2011; 17(8): CR449-55